Mohamed Elsaid
@must.edu.eg
Faculty of Medicine
Misr University for Science and Technology
Scopus Publications
Scopus Publications
Ammar Mektebi, Mohamed Elsaid, Tularam Yadav, Fatima Abdallh, Mohamad Assker, Abdelmonem Siddiq, Reem Sayad, Motaz Saifi, and Ramadan Abdelmoez Farahat
Springer Science and Business Media LLC
Abstract Introduction Mpox is a zoonotic viral disease that emerged in May 2022 and has since shown a high prevalence in non-mpox-endemic areas, resulting in an outbreak that caused more than 84,000 cases in 110 countries around the globe. Several vaccines are available to prevent the disease, and multiple studies have been conducted to assess the attitudes of different populations toward receiving the mpox vaccine. This study systematically reviews all the studies conducted on mpox vaccine acceptance/hesitancy among healthcare workers. Methods A systematic literature search was conducted through four electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar, up to March 2023. Studies that described mpox vaccine acceptance/hesitancy among healthcare workers were included, and the data were extracted using a uniform extraction sheet. Following the extraction, the meta-analysis included ten studies with 7322 healthcare workers. Three researchers independently assessed the risk of bias in the included study using the Newcastle–Ottawa Scale (NOS). Results Ten studies were included in the review. This review indicates that the prevalence of mpox vaccine acceptance was 58.5%, and the prevalence of mpox vaccine hesitancy was 41.5%. There was a higher prevalence of acceptance in countries located in Asian and African areas compared to those in North America and Europe, estimated at 68% and 44.3%, respectively. Among the studies conducted solely among physicians, there was a high prevalence of mpox vaccine acceptance, at 77.1%, compared to 49% in studies that included all healthcare workers. Conclusion There is a significant variation in the prevalence of mpox vaccine acceptance among different populations. Further research is needed to identify the factors that contribute to this variation and to develop interventions to increase vaccine acceptance. In addition, it is important to promote research on mpox vaccine acceptance and hesitancy among healthcare workers in countries where data is limited. This research will help policymakers develop effective policies to increase acceptance and reduce the disease burden.
Mohamed Elsaid, Arvind Nune, Aml M. Brakat, Ayush Anand, Mahmoud Alashwah, Ahmed Maher, Nitu Lama, and Criselle Angeline C. Peñamante
Springer Science and Business Media LLC
Abstract Background The American Society of Haematology defines immune thrombocytopenic purpura (ITP) as a common hematologic disorder characterized by a transient or long-term decrease in platelet counts (< 100 × 109/L.), purpura, and haemorrhagic episodes caused by antiplatelet autoantibodies, with the exclusion of other clinical conditions. We aimed to systematically determine the incidence of ITP in adults and children following influenza vaccination, the duration between vaccination and the occurrence of ITP, and to identify predictors of ITP after the vaccine. Methods We searched PubMed, Cochrane Library, Google Scholar, Web of Science, Scopus, and Science Direct. We included primary studies that assessed the occurrence of immune thrombocytopenia in individuals who had received any influenza vaccine (primary or booster dose), regardless of the dosage, preparation, time of administration, or age of the participants. We excluded studies that were (a) Narrative, scoping, and umbrella reviews ;(b) studies with no accessible full text, abstract-only studies, or (c) Overlapping or unreliable data. The risk of bias in the included studies was assessed using the Joanna Briggs Institute (JBI) tool. We categorized studies for qualitative analysis based on study design. Descriptive statistics were used to summarize quantitative data, including the incidence of ITP after influenza vaccination. Results Out of 729 articles retrieved from the database search, we included 24 studies. All patients identified and included in this systematic review presented with immune thrombocytopenia, determined by their platelet count. The period between vaccination and the occurrence of ITP ranged from (2:35 days). The mean duration was 13.5 days. The analysis revealed a statistically significant incidence rate ratio (IRR) = 1.85,95% CI [1.03–3.32] of ITP occurrence after 42 days. Conclusions Influenza-associated ITP is uncommon, self-limiting, non-life-threatening, and curable. None of the patients reported having severe adverse events or death. Further studies are required to confirm the exact incidence of the ITP to better understand the pathophysiology of ITP development post-influenza vaccination.
Mohamed Elsaid, Arvind Nune, Deyaa Hesham, Fatma Mohamed Fouad, Hamsa Hassan, Heba Hamouda, Huda Sherif, Maya Magdy Abdelwahab, Nourelhoda Hegazi, and Yasmena Abd El-Rahman
Springer Science and Business Media LLC
Abstract Background Although SARS-CoV-2 vaccines are generally safe, there are growing concerns about their link to a potentially life-threatening multi-system inflammatory syndrome following vaccination (MIS-V). We conducted this systematic review to elucidate the prevalence of MIS, severity, treatment, and outcomes following SARS-CoV-2 vaccination. Methods We searched PubMed, Scopus, ScienceDirect, Google Scholar, Virtual Health Library (VHL), Cochrane Library, and Web of Science databases for articles and case reports about MIS-V. We performed a qualitative analysis of individual cases from the included studies. Results Of the 1366 studies identified by database search, we retrieved twenty-six case reports and two cohort studies. We analyzed the data of 37 individual cases extracted from 27 articles. The average age of the cases included in this review was 18 (1–67) years, with the most being male (M: F 3.1:1). Of the 37 included cases, the cardiovascular system was the most affected system by MIS (36, 97.3%), followed by the gastrointestinal tract (32, 86.5%). Conclusion MIS after SARS-CoV-2 vaccinations can be fatal, but the incidence is low. Prompt recognition of MIS and ruling out the mimickers are critical in the patient’s early recovery.
Fatma Mohamed Fouad and Mohamed Elsaid
Elsevier BV
Karol Kamel, Hadeer Nasr, Sherifa Tawfik, Ahmed Azzam, Mohamed Elsaid, Mohamed Qinawy, Ahmed Kamal, and Heba Taher
Springer Science and Business Media LLC
Abstract Background A urachal cyst has a rare incidence that has been reported as 1/5,000 live birth. Case presentation We report two patients with a complicated urachal cyst, a 5-year-old female who presented to the emergency department with severe abdominal pain and a 3-year-old female presenting with abdominal pain and constipation. Upon laparoscopic exploration both patients had complicated urachal cysts which were adherent to the urinary bladder. Conclusion Complicated urachal cysts can present with acute abdominal pain.
Abdelrahman Yousry Afify, Mohamed Hady Ashry, Mohammed Ahmed Sadeq, and Mohamed Elsaid
Springer Science and Business Media LLC
Abstract Background Several reports examined the survival of laryngeal cancer (LC) patients, most of these studies only focused on the prognosis of the disease, and just a small number of studies examined non-cancer-related causes of death. The objective of the current study is to investigate and quantify the most common causes of deaths following LC diagnosis. Methods The data of 44,028 patient with LC in the United States diagnosed between 2000 and 2018 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) program and analyzed. We stratified LC patients according to various demographic and clinical parameters and calculated standardized mortality ratios (SMRs) for all causes of death. Results Over the follow-up period, 25,407 (57.7%) deaths were reported. The highest fatalities (11,121; 43.8%) occurred within 1–5 years following LC diagnosis. Non-cancer causes of death is the leading cause of death (8945; 35.2%), followed by deaths due to laryngeal cancer (8,705; 34.3%), then other cancers deaths (7757; 30.5%). The most common non-cancer causes of death were heart diseases (N = 2953; SMR 4.42), followed by other non-cancer causes of death (N = 1512; SMR 3.93), chronic obstructive pulmonary diseases (N = 1420; SMR 4.90), then cerebrovascular diseases (N = 547; SMR 4.28). Compared to the general population, LC patients had a statistically significant higher risk of death from all reported causes. Conclusions Non-cancer causes of death is the leading cause of death in LC patients, exceeding deaths attributed to LC itself. These findings provide important insight into how LC survivors should be counselled regarding future health risks.
Haneen Abaza, Kuchalambal Agadi, Ayush Anand, and Mohamed Elsaid
Springer Nature Switzerland
Ramadan Abdelmoez Farahat and Mohamed Elsaid
Elsevier BV
Mohamed Elsaid, Mostafa Ayman Nasef, and Nguyen Tien Huy
Informa UK Limited
ABSTRACT Background: Vaccination has been known to reduce morbidity and mortality of infectious diseases since the emergence of the 1st vaccine in the 18th century. That’s why global efforts are directed toward finding a vaccine for COVID-19 in order to eliminate its threat. The current pandemic of COVID-19 has changed the world affecting all fields significantly as a result of the preventive measures including locking down, social distancing, obligatory mask wearing, stopping flights, etc. The medical field is clearly the most significantly affected starting from altering most of the research efforts toward the new virus passing through the inadequate number of physicians as well as unavailable intensive care unit (ICU) beds. In order to break the restricted preventive measures, we need to minimize the newly infected cases which can be achieved by reaching adequate herd immunity. Moreover, calculating the basic reproduction number (R0) of COVID-19 is crucial to estimate the herd immunity threshold (Ic). Methods: In this review, we searched PubMed for studies that mentioned the R0 of COVID_19, SARS, and MERS as well as measles, Zika and dengue virus to calculate the herd immunity threshold and the minimal vaccination coverage. Results: The value of R0 could vary for the same disease and consequently the herd immunity threshold as well as the vaccination coverage. The R0 of COVID-19 ranged widely through various articles from 1.4 to 6.68. As a result, the herd immunity threshold would range from 28.57% to 85.03%. However, the vaccination coverage depends also on the effectiveness of the vaccine which is still unknown. Conclusion: The calculations of vaccination coverage include many variables such as the R0 of the disease, Ic that depends on that value as well as sensitivity and specificity of the vaccine itself.